secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGM Biosciences, Inc. (—)
CIK:        0001496323
Form:       8-K/A
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0000950170-24-123677
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

IGM Biosciences estimates $11.7M-$14.4M in restructuring charges for strategic pivot
--------------------------------------------------------------------------------

- Total restructuring charges estimated between $11.7M and $14.4M.
- Cash costs: $3.4M to $5.7M for severance and termination; $0.1M to $0.3M for contract termination.
- Non-cash stock-based compensation: $8.2M to $8.4M.
- Substantially all charges expected in Q3 2024; restructuring complete by Q2 2025.
- Amends Oct 3, 2024 8-K disclosing shift away from aplitabart and oncology R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496323/000095017024123677/0000950170-24-123677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496323/000095017024123677/igms-20240927.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer